We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Secukinumab Exhibits Sustained and Stable Response in Patients with Moderate-to-Severe Psoriasis: Results from the SUPREME Study.
- Authors
COSTANZO, Antonio; RUSSO, Filomena; GALLUZZO, Marco; STINGENI, Luca; SCUDERI, Roberta; ZICHICHI, Leonardo; PAPINI, Manuela; DI COSTANZO, Luisa; CONTI, Andrea; BURLANDO, Martina; CHIRICOZZI, Andrea; GAIANI, Francesca Maria; MUGHEDDU, Cristina; MUSUMECI, Maria Letizia; GISONDI, Paolo; PIASERICO, Stefano; DAPAVO, Paolo; VENTURINI, Marina; PAGNANELLI, Gianluca; AMERIO, Paolo
- Abstract
Secukinumab, a fully human monoclonal antibody, neutralizes interleukin-17A, a cornerstone cytokine driving the multiple manifestations of psoriasis. This post-hoc analysis of the SUPREME study was performed to determine the sustainability of response to secukinumab in terms of Psoriasis Area and Severity Index (PASI) 90 in patients with moderate-to-severe plaque psoriasis. Based on PASI 90 response at week 16, patients were stratified as PASI 90 responders (PASI90R, n = 337) or non-responders (PASI90NR, n = 72). At week 20, 94.2% (n = 295/313) achieved PASI 90/100 response in PASI90R, with response maintained through week 48 (89.6%, n = 189/211). An increased proportion of patients achieved PASI 90/100 response in PASI90NR (week 20: 29.9%, n = 20/67; week 48: 57.1%, n = 20/35). Overall, 64.4% patients achieved absolute PASI score = 0 at week 24 with response sustained to week 48 (66.9%). Secukinumab showed sustained and stable efficacy in maintaining PASI 90 response in patients with moderate-to-severe plaque psoriasis up to week 48.
- Subjects
PSORIASIS; MONOCLONAL antibodies; CYTOKINES
- Publication
Acta Dermato-Venereologica, 2021, Vol 101, Issue 10, p1
- ISSN
0001-5555
- Publication type
Article
- DOI
10.2340/00015555-3816